Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study
Wenxia Hu,Bin Li,Nan Geng,Xin He,Hui Ge,Ping Wang,Cuimin Ding
DOI: https://doi.org/10.2147/IJGM.S303717
IF: 2.145
2021-06-21
International Journal of General Medicine
Abstract:Wenxia Hu, Bin Li, Nan Geng, Xin He, Hui Ge, Ping Wang, Cuimin Ding Department of Respiratory Medicine, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, People's Republic of China Correspondence: Cuimin Ding Department of Respiratory Medicine, Fourth Hospital of Hebei Medical University, 12 Jian-Kang Road, Shijiazhuang, 050000, People's Republic of China , Tel +86 139-3385-2787 Email Background: This study aimed to explore associations between PDL1 polymorphisms and efficacy of apatinib for patients with previously treated advanced non–small cell lung cancer (NSCLC) in a real-world setting. Methods: We retrospectively recruited 148 patients with previously treated advanced NSCLC from January 2015 to December 2019 continuously. Clinical efficacy in patients receiving apatinib treatment was evaluated. Adverse reactions were documented during treatment. Biological specimens of peripheral blood and cancer tissue biopsies were obtained for the genotyping of genetic variations in PDL1 and corresponding gene-mRNA expression, respectively. Univariate association analysis between the status of PDL1 genetic variations and survival was performed with Kaplan–Meier survival analysis. Results: The objective response rate of the 148 patients was 17.6% and disease-control rate 68.9%. Prognostic data suggested that median progression-free survival (PFS) was 3.8 (95% CI 3.13– 4.47) months and median overall survival (OS) 10.5 (95% CI 9.06– 11.95) months. Regarding PDL1 genetic variation, only rs2297136 was of clinical significance. Prognosis analysis revealed that PFS and OS for the rs2297136 genotype were significantly different. Median PFS of patients with TC/CC and TT genotypes was 3 and 4.5 months, respectively ( P =0.006). Median OS of the two genotypes was 9 and 11.6 months, respectively ( P =0.04). Furthermore, the safety profile suggested that the most common adverse reactions were hypertension, dermal toxicity, fatigue, and oral toxicity. This study failed to find any significant association between adverse reactions and rs2297136. Interestingly, mRNA-expression analysis demonstrated that mRNA expression of PDL1 in biopsy cancer–tissue specimens was significantly different based on rs2297136-genotype status ( P < 0.001). Conclusion: The PDL1 polymorphism rs2297136 could be used as a potential biomarker for the prognosis of patients with NSCLC receiving apatinib monotherapy. Keywords: NSCLC, apatinib, PDL1 , genetic variation, clinical outcome, safety, biomarker Lung cancer is the most common solid tumor and has the highest morbidity and mortality worldwide. According to the latest cancer-epidemiology data, 0.815 million new cases and 0.715 million new deaths due to lung cancer are observed in China currently. 1 As the most common histological subtype, non–small cell lung cancer (NSCLC) accounts for approximately 85% in lung cancer. 2 Recently, targeted drugs with different mechanisms of action were developed based on common somatic gene-mutation profiles with significant survival benefits. 3 Unfortunately, approximately half the patients with NSCLC in China lack one potentially significant driver-gene mutation, and correspondingly only platinum-based chemotherapy regimens are available as first-line treatment. 4 Chemotherapy efficacy is dismal, with objective response rate (ORR) 20%–30% and median progression-free survival (PFS) 4–5 months. 5 Single-agent chemotherapy with docetaxel, pemetrexed, gemcitabine, and immunotherapy are alternative second-line treatment options, with additional benefits in prolonging survival after first-line treatment. 6 However, the advantages of traditional second-line treatment are limited currently. Immunotherapy drugs have been licensed in recent years, and the low ORR of P D1/ P DL 1 inhibitors has exhibited that patients who could benefit from an immunotherapy drug are thus also limited. 7 Consequently, patients with advanced NSCLC are in urgent need of therapeutic drugs upon disease progression after standard treatment. Angiogenesis was identified as an important therapeutic strategy for solid tumors and was proven to be an essential condition in the process of tumor growth according to the theory of Folkman in 1971. 8 Antiangiogenic drugs exhibit potential anticancer activity in treatment show advanced NSCLC. Bevacizumab and ramucirumab exhibit potential survival benefits for patients with NSCLC as first -Abstract Truncated-
medicine, general & internal